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Summary In order to study the growth kinetics ofbreast tumours during long-term hormonal withdrawal, we
developed a transplantable, invasive mammary carcinoma EMR-86 that originated in a female WAG/Olac rat
bearing a subcutaneously implanted oestrogen pellet (EP). Outgrowth of transplanted tumours occurs only in
the presence of an EP, and metastases are formed in lungs and regional lymph nodes. Subsequent EP removal
induces rapid regression. However, tumours do not disappear completely, as small nodules persist. These
dormant tumour remnants can be restimulated even after long periods. Because EP-stimulated tumours
regressed after treatment with bromocriptine and dormant tumours in non-oestrogenised rats grew out after
treatment with perphenazine, prolactin is the major growth-stimulating hormone in this model. Cell kinetics in
the growing, regressing and dormant phase were studied by immunocytochemical detection of DNA-
incorporated bromodeoxyuridine (BrdUrd) in tissue sections. BrdUrd labelling indices decreased from
21.6 ± 3.0% to less than 1% within 7 days after EP removal. After prolonged hormonal withdrawal (up to 90
days) BrdUrd-labelled tumour cells could always be demonstrated (range 0.4-0.8%), without a concomitant
increase in tumour volume. Additional treatment either with bromocriptin or with ovariectomy could not
significantly reduce this residual proliferative activity, as demonstrated by continuous BrdUrd labelling
experiments. The results indicate that in vivo dormancy may represent a steady state of cell division and cell
loss, rather than an accumulation of cells in a non-cycling Go state.
In hormone-dependent rodent breast cancer models, with-
drawal of the growth stimulus can lead to tumour regression
(Briand, 1983). Unless the regression is interrupted by rapid
outgrowth of hormone-independent tumour cells, a period of
dormancy may follow in which a certain population of
residual tumour cells persists, retaining the capacity to
resume growth upon restimulation. This endocrine-related
dormancy has been observed in various tumour models (in-
cluding MCF-7 human breast cancer cells in nude mice),
depending on different hormones for growth (Noble &
Hoover, 1975; Gullino et al., 1972; Jordan et al., 1979; Shafie
& Grantham, 1981; Kitamura et al., 1978; Briand et al.,
1982). As such, it cannot be excluded that a similar situation
may occur in patients with early breast cancer during
adjuvant hormonal therapy.
To our knowledge, no detailed cell kinetic studies have
been performed on experimental mammary tumours in a
dormant state. A reason for this may be that in most animal
models reproducible evaluation is seriously hampered by the
rapid appearance of autonomously growing tumour cells. In
order to investigate the growth-kinetic effects of long-term
hormonal withdrawal on residual tumours, we developed a
transplantable mammary carcinoma in oestrogenised female
WAG/Olac rats, because it has been documented that pro-
gression towards autonomy is remarkably slow in mammary
tumours arising oestrogen pellet (EP)-bearing rats (Noble &
Hoover, 1975). In this study we evaluated the hormonal
requirements and metastasising capacities of this EMR-86
tumour, as well as its phenotypic and cell kinetic character-
istics during growth, regression and dormancy. Cell kinetics
were investigated using BrdUrd labelling techniques. The
results indicate that in vivo dormancy may represent a steady
state of cell division and cell loss, rather than an accumula-
tion of cells in a non-cycling Go state.
Materials and methods
Animals
Female Wistar-derived WAG/Olac rats, originally obtained
from the Glaxo laboratories (Greenford, Middlesex, UK)
were purchased from the Harlan/Olac company (Zeist, The
Netherlands) and used at the age of 3-5 months. Food and
water were provided ad libitum.
Tumour induction and transplantation
Tumours were induced and maintained in rats carrying
oestrogen-pellets (EPs), subcutaneously implanted in the
intrascapular region of the neck. Pellets could be palpated
and surgically removed at all times. Fragments of growing
tumours could be successfully frozen and stored for trans-
plantation in liquid nitrogen in RPMI 1640 medium contain-
ing 10% rat serum and 10% dimethyl sulfoxide (Baker
Chemicals, Deventer, The Netherlands).
Tissue fragments (1-2 mm3) were transplanted subcutan-
eously into the flanks at four sites per rat, unless stated
otherwise. All surgical procedures were performed under
ether anaesthesia.
Endocrine treatment
EPs consisted of 2 mm long segments of 3 mm diameter
silicone tubing, containing 1.5 mg 17p-oestradiol (Sigma, St
Louis, MO) in a 1:3 cholesterol/paraffin base (Blankenstein,
1980). Previously, it was demonstrated that plasma oestradiol
levels of EP-bearing WAG/Olac rats remain above 3.67 x
10-°1mol 1' for at least 2 months, whereas plasma levels of
prolactin are 200-300 gg- 1'. In untreated controls, values
are 1.8 x 10 '0mol 1' and 20 ig 1'- respectively (Blanken-
stein et al., 1977; Blankenstein et al., 1984).
Treatments to inhibit or stimulate prolactin secretion
consisted of daily oral administration of 5 mg kg-' bromo-
criptine and 5 mg kg-' perphenazine, respectively. Both com-
pounds were suspended in 0.5% carboxymethyl cellulose in
20% propylene glycol.
Ovariectomy was performed via two dorso-lateral incisions.
DNA ploidy measurements
Samples for flow cytometry were frozen and stored in citrate
buffer (pH 7.6) containing 10% DMSO. After thawing,
tissues were minced with razor blades and as a ploidy stan-
dard trout erythrocytes were added. Suspensions of single
nuclei were prepared as described by Vindel0v et al. (1983)
and stained with propidium iodide (Sigma, St Louis, MO).
Samples were measured on a FACScan (Becton Dickinson,
Mountain View, CA).
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Growth kinetics
Tumour growth was monitored using calipers; tumours were
measured twice weekly and volumes calculated by the pro-
duct of three orthogonal diameters multiplied by x/6 (Deth-
lefsen et al., 1968). Histology was evaluated in haematoxylin-
eosin stained sections of formalin fixed, paraffin embedded
tissue specimens.
In order to estimate the fraction of S-phase cells, animals
were intraperitoneally injected with 50 mg kg-' 5-bromo-
deoxyuridine (BrdUrd, Sigma) in saline and sacrificed after
1 h. In order to identify cells passing through the S-phase
during longer labelling periods (96 h), BrdUrd was con-
tinuously infused using Alzet osmotic pumps (model 2MLI,
Alza corp., Palo Alto, Ca) filled with 20 mg BrdUrd in 2 ml
saline. Before s.c. implantation in the back of the animals,
efficacy of the pumps was verified by incubating overnight in
saline.
BrdUrd-labelled tissues (including small intestine as inter-
nal control) were fixed in phosphate-buffered formalin and
embedded in paraffin. Immunohistochemical staining for
DNA-incorporated BrdUrd in 4ym sections was performed
as described previously (van Dierendonck et al., 1987).
Briefly, after blocking dewaxed sections for endogenous
peroxidase, cellular DNA was denatured in 0.07 N NaOH in
70% ethanol (10min, RT), followed by digestion with
0.1 mg ml-' Proteinase K (Boehringer, Mannheim, Germany)
in 10 mM Tris-HCI-2 mM CaC12, pH 7.0 (10 min, 37°C). After
washing in PBS, sections were incubated with antio-BrdUrd
mouse monoclonal antibody (IU-4, a gift from Dr F.
Dolbeare, Livermore, CA). Subsequently, a peroxidase-
conjugated rabbit-anti-mouse IgG antibody (Dakopatts,
Glostrup, Denmark) was applied and staining developed
using diaminobenzidine-H202 as substrate. Sections were
lightly counterstained with haematoxylin. To determine the
fraction BrdUrd containing nuclei, 1,000-2,000 nuclei of
epithelial cells were counted by systematic random sampling
using a Leitz orthoplan microscope equipped with a Weibel
II graticule (Graticules Ltd, Tonbridge, UK).
Results
Origin and DNA ploidy ofthe EMR-86 tumour
The primary tumour, from which the EMR-86 model was
derived, arose 9 months after s.c. implantation of an EP in a
female rat. Upon subsequent transplantation into an un-
treated rat no growth was detected until an EP was inserted
afterwards. These hormone-dependent tumours were used for
further transplantation.
DNA histograms of early passages displayed either single
or multiple overlapping peaks ranging from 1.36 to 1.48.
This genetic heterogeneity was less prominent after the 5th
passage and thereafter, displaying a DI of 1.37 (Figure la).
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Figure 1 Flow cytometric DNA histograms of EMR-86
tumours. a, 5th passage flank tumour; b, 10th passage flank
tumour after 30 days of dormancy; TRBC: trout red blood cells.
Histology during EP stimulatedgrowth
EP stimulated EMR-86 tumours were histologically classified
as invasive ductal carcinomas, with a cribriform growth pat-
tern and large areas with comedo type necrosis (Figure 2a)
(van Zwieten, 1984). Ductal structures were lined with
stratified epithelium and possessed large lumina, filled with
necrotic material. Myoepithelial cells could not be identified.
Sometimes tumours contained small foci of squamous meta-
plasia, which is the most common metaplastic variant in
human ductal breast carcinomas (McDivitt et al., 1968) and
has been described earlier in oestrogen-induced rat mammary
tumours (Noble et al., 1975). In the first six passages
vacuolated epithelial cells and sebaceous differentiation were
sometimes observed, but no other morphological cbanges
occurred during 12 passages of transplantation.
Growth kinetics during EP stimulation
In oestrogenised rats, the take-rate of nitrogen stored tissue
blocks was 96.6% (n = 319 transplants), whereas tumours
transplanted into non-oestrogenised animals never grew out.
However, such transplants always grew out after postponed
EP implantation. An example of EP-manipulated tumour
growth is given in Figure 3.
The tumour doubling time, estimated by volume measure-
ments, decreased during the first four passages to stabilise
after the 5th passage at 2.6 ± 0.7 days (mean ± s.d., n = 40).
BrdUrd labelling-index (LI) of stimulated tumours was
21.6 ± 3.0% (mean ± s.d., n = 16). As indicated by the posi-
tion of the labelled cells, proliferation in the ducts occurred
in an orderly fashion, predominantly in the basal part, close
to the stroma (Figure 2b). In cell layers close to the lumen,
hardly any cell division could be detected.
Histology andgrowth kinetics during regression
Following EP removal, 56 of 66 rats bearing established
tumours responded with almost complete regression. Within
3 weeks, tumours with initial volumes ofmore than 1,000 mm3
became too small for accurate caliper measurements (i.e.
smaller than 50 mm3), but remained palpable as small
nodules.
Morphological and kinetic changes were investigated in
five rats bearing four 7th passage tumours at 0, 1, 3, 7 and
17 days after EP removal. During the first 3 days after EP
removal no gross changes in morphology were noted. The
only histological sign of increased cell loss seemed to be a
higher frequency of apoptotic nuclei, identified by the intense
basophilic staining of condensed chromatin in individutal cells
(Wyllie et al., 1980) (Figure 2c). Seven days after EP
removal, the large duct-like structures had changed into
much smaller epithelial nests in which lumina were hardly
distinguishable. After 17 days only small clusters of epithelial
cells remained. The BrdUrd labelling index of tumour cells
decreased shortly after EP removal, whereas in stromal cells
labelling indices began to decrease after 3 days (Figure 4).
After 30 days of hormonal withdrawal, the epithelial/
stromal cell ratio was decreased, as observed from relative
changes between diploid an aneuploid peaks in flow cytomet-
ric DNA histograms (Figure lb).
Histology andgrowth kinetics after long-term hormonal
withdrawal
In order to investigate whether persisting tumour nodules
gradually disappeared or remained unchanged, and whether
cell division was still present, histology and BrdUrd labelling
were evaluated at 30, 60 and 90 days after EP removal in
three rats per group, bearing four 10th passage tumours
each. At 30 days after EP removal, tumour histology was
comparable to that after 17 days of regression, except that
the epithelial clusters contained fewer cells. After 60 days
these clusters had become even smaller, whereas no marked
differences were observed comparing 60 and 90 days. In allENDOCRINE-RELATED TUMOUR DORMANCY 465
d
Figure 2 Histology and immunocytochemical BrdUrd staining of EMR-86 tumours. a, Comedo-type necrosis and cribriform
growth pattern of an EP stimulated EMR-86 tumour (10th passage), H and E, x 100; b, BrdUrd staining after 6 h of labelling
during EP stimulated growth, demonstrating cell division in the basal part of a duct. x 200; c, Apoptotic nuclei (arrowheads), 3
days after EP removal. H and E, x 1,000; d, Dormant flank tumour after 30 days of hormonal withdrawal, with the largest
epithelial cell clusters in the periphery. H and E, x 160; e, BrdUrd-containing cell in a dormant tumour, after 1 h of labelling.
x 1,000; f, Immunohistochemical detection of DNA-incorporated BrdUrd after 96 h of labelling in a dormant tumour 30 days
after EP removal. x 400; g, small lung metastatasis. H and E, x 200.
dormant tumour nodules the largest clusters ofepithelial cells
were present in the periphery. In the centre, where the stroma
has a scirrhous appearance, only small groups of tumour
cells were present (Figure 2d).
Immunohistochemical staining showed few BrdUrd
labelled cells that were evenly distributed over the section.
These cells were of the same morphology as the unstained
neighbouring tumour cells (Figure 2e) and stained positively
for cytokeratin (data not shown). Labelling indices in the
regressed tumours were 0.4 ± 0.1% (mean ± s.d.) after 30
days of hormonal withdrawal, 0.4 ± 0.1% after 60 days and
0.8 ± 0.6% after 90 days.
After 30, 60 and 90 days three rats received an EP in order
to evaluate regrowth. Every dormant tumour resumed
growth, which was also observed in four other rats that were
restimulated after more than 30 days of hormonal with-
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Figure 3 Growth behaviour of 10th passage EMR-86 flank
tumours. Together with the tumours an EP is implanted. Follow-
ing the rapid regression after EP removal, tumours become too
small for accurate caliper measurements, but often remain pal-
pable. Subsequent EP insertion results in regrowth.
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Figure 4 Effect of EP removal upon BrdUrd-LI of epithelial
0-0 and stromal cells 0---0 in EMR-86 flank tumours.
Bars: s.d.
drawal, with a longest dormancy period evaluated of 270
days. Volume doubling times of these regrowing tumours
were similar to those of normal EP-stimulated tumours, as
were histology and DNA-index at necropsy. The lag-time to
exponential growth was less than 1 week upon restimulation
after 30 days of hormonal withdrawal, whereas approxi-
mately 3 weeks when restimulated after 60 days. The lag time
did not further increase after longer periods ofdormancy. No
clues for the extinction of dormant tumours have been
obtained.
Hormone dependency
Since implanted EPs have been shown to stimulate prolactin
release in the pituitary (Blankenstein et al., 1984), we
evaluated the contribution of this hormone to the growth of
EMR-86 tumours. To inhibit prolactin release, four oestro-
genised animals, bearing multiple 1 cm3 sized 6th passage
tumours, were treated for 9 days with the dopamine-agonist
bromocriptine. This resulted in rapid tumour regression, des-
pite the presence of an EP. Contrariwise, regrowth of
tumours was observed after the stimulation of prolactin by
17 days of perphenazine treatment in four rats bearing
regressed tumours after EP removal. The effects on tumour
growth were reversible after discontinuation of the treatments
(Figure 5). These data strongly suggest an important role for
prolactin in the growth stimulation of EMR-86 tumours.
Figure 5 Influence of prolactin on EMR-86 tumour growth. a,
Nine days bromocriptine treatment of an EP stimulated rat; b, 17
days perphenazine treatment of rat with regressed tumours after
EP removal.
To assess whether proliferation of residual cells after EP
removal could be further reduced by additional treatment
with either ovariectomy or bromocriptine, the fractions of
labelled tumour cells were compared after continuous
BrdUrd administration. It was preferred to label 96 h instead
of one, since it seemed unlikely to detect significant
differences between the very low labelling indices as observed
after BrdUrd pulse-labelling. After 30 days of treatment, with
three rats per group, the fraction of tumour cells that had
incorporated BrdUrd during 4 days of labelling was
7.1 ± 1.1% (mean ± s.d.) after EP removal only; 10.8 ± 2.9%
in the group that had received additional bromocriptine and
13.7 ± 2.7% after EP removal plus ovariectomy. These
percentages were not significantly different after one-way
analysis of variance and therefore did not provide evidence
for further reduction of residual proliferation. Figure 2f
shows an example of the detected BrdUrd following 96 h of
labelling in a dormant tumour at 30 days after EP removal.
EP-independent growth
In 14 out of 81 rats (17.3%) autonomous tumour growth
developed following EP removal. In 11 of these, it occurred
in all tumours present and with a simultaneous onset. This
became detectable within 3 weeks after EP removal. Three of
these rats were treated by ovariectomy and three others
received bromocriptine. The treatments induced tumour
regression with subsequent dormancy in two of three and in
all three rats, respectively, suggesting it concerned mainly
'hormone-sensitive' clones (Noble & Hoover, 1975).
In the remaining three of the 14 rats regrowth occurred
after more than 50 days of dormancy, affecting only one of
the four tumours present in an animal.
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Metastatic behaviour
Histology of large lung and lymph node metastases was
similar to that of flank tumours, whereas in small metastases
the large ductal structures were less prominent (Figure 2g).
DNA-indices and S-phase fractions were identical to those of
flank tumours.
In general, metastatic disease became relatively late detect-
able: at sacrifice of rats bearing flank tumours of
1,500-2,000 mm3, lung and lymph node metastases were
often only microscopically identified. However, after removal
of a small solitary tumour (450mm3), the animal died of
lung metastases 44 days later, indicating that metastatic
spread had occurred already at an early stage.
No histological evidence was obtained for dissemination to
organs other than regional lymph nodes and lungs. This was
further investigated by s.c. transplantation of minced tissue
of lungs, axillary nodes, adrenals, ovaries and bone marrow
from a rat with EMR-86 flank tumours into EP-bearing
recipients. This did not provide evidence for the presence of
viable tumour cells at other sites than regional lymph nodes
and lungs.
In order to evaluate the hormone-dependency of meta-
stases, fragments of lung nodules were subcutaneously trans-
planted into the flanks of three rats. They grew rapidly in an
oestrogenised rat, whereas the other two rats without an EP
did not show evidence of tumour growth, unless after EP
implantation.
Discussion
This study describes the phenotypic and cell kinetic
characteristics of a mammary carcinoma that grows in
oestrogenised rats and becomes dormant after hormonal
withdrawal. In tumours that are induced and maintained
under superphysiological levels of hormone, progression
towards autonomy is extremely slow and long periods of
latency can be achieved, as was initially described by Noble
and co-workers (Noble et al., 1975; Noble & Hoover, 1975;
Noble, 1977) and later confirmed by others (Senior et al.,
1985). This relative stability with respect to hormone-
dependency is probably related to the selection of the most
rapidly growing hormone-dependent tumour cell subpopula-
tion from transplants in EP bearing hosts (Noble & Hoover,
1975).
The EMR-86 tumour combines highly hormone-dependent
growth characteristics with a truly malignant phenotype. This
combination was seldom encountered by Noble and also
distinguishes EMR-86 carcinomas from the widely used
DMBA and NMU-induced hormone-dependent rat mam-
mary tumours, that are in general of low malignancy (Russo
et al., 1990). Histologically, carcinomas of the cribiform-
comedo type are the most frequently found invasive tumours
in oestrogenised WAG rats (van Zwieten, 1984), and the lack
of myoepithelial cells is described as a consistent
phenomenon in the progression to a highly malignant
phenotype (Rudland & Barraclough, 1988). The aneuploid
DNA-content, also indicative of the tumour's malignant
nature, served to monitor the stability of the tumour and to
verify lineage.
Although growth of EMR-86 tumours was manipulated
by oestradiol-containing pellets, the response to treatments
with bromocriptine and perphenazine demonstrated a major
role for prolactin as growth-promoting hormone, as in most
rat breast cancer models (Welsch, 1985). In this respect, the
EMR-86 models also resembled the MTW-9 breast carcinoma
that remains dormant in the absence of an implanted
prolactin-releasing pituitary tumour (Gullino et al., 1972).
The precise mechanism by which oestradiol exerts its effects
on prolactin secretion has not been completely elucidated.
It has recently been reported that, apart from the
hypothalamus under physiological circumstances the
intermediate lobe of the posterior pituitary may also be
considered as a mediator (Murai & Ben-Jonathan, 1990;
Ben-Jonathan, 1985). Oestrogenisation of rats leads to
hypertrophy of the pituitary gland or even development of
adenomas (Cutts & Froude, 1968; Lloyd, 1983) and increas-
ing plasma levels of prolactin have been found during the
months after EP implantation in WAG rats (Blankenstein
et al., 1984). Therefore, prolactin rather than oestrogen may
have been involved in the induction of the primary EMR-86
tumour. Furthermore, the simultaneous onset of regrowth
in multiple tumours in a single rat, observed in a few
instances after EP removal, could have been related to
increased or autonomous prolactin secretion by a hyper-
plastic pituitary lesion. The implication of prolactin as the
systemic factor involved in EP-independent regrowth is
strengthened by the finding that bromocriptine or ovariec-
tomy could reverse this process.
When we studied tumour regression shortly after hormonal
withdrawal, a rapid decrease in tumour volume was observed
to be preceded by an important decline in BrdUrd LI. Lan-
caster and colleagues found that one week after ovariectomy
NMU-induced rat mammary tumours showed a visible in-
crease in the amount of necrosis and areas of glandular cell
death, whereas myoepithelial and stromal cells remain
unaffected (Lancaster et al., 1990). Such changes were not
readily observed in regressing EMR-86 tumours. Instead,
cells showing the distinctive characteristics of apoptosis
became more conspicuous (Wyllie et al., 1980). This pro-
grammed cell death occurs in many hormonally regulated
epithelia (Kerr et al., 1972), e.g. during the menstrual cycle in
the resting human breast (Ferguson & Anderson, 1981) and
has recently been described in regressing MCF-7 human
breast tumours in nude mice (Kyprianou et al., 1991).
Within 2 to 3 weeks after EP removal, the rapid phase of
tumour regression had ended. In the remnant nodules further
regression, if any, was very gradual, since no apparent
differences in histology and growth kinetics were observed
between 60 and 90 days of dormancy. Even where tumours
were barely palpable at the time of EP removal they always
resumed growth upon restimulation after many months of
dormancy. Furthermore, the similar lag-times from the
moment of EP reimplantation to exponential growth after 2
months of dormancy compared to longer periods of regression,
suggested a constant number of clonogenic cells.
We demonstrated that dormant EMR-86 tumours did not
entirely consist of non-cycling (Go) cells, but also contained a
cycling cell population. This seems in contrast with results
from studies on oestrogen-dependent Leydig cell tumours, in
which no mitotic figures are observed during endocrine-
related dormancy (Huseby, 1983). However, the likelihood of
detecting proliferative activity is greater when a large com-
partment of the cell cycle is examined, such as the S-phase as
defined by BrdUrd pulse-labelling, and even more so by
continuous BrdUrd infusion for prolonged periods. The lat-
ter approach revealed a considerable fraction of cells passing
through the S-phase, during 96 h of labelling. In the absence
of a concomitant increase in tumour volume, this finding
implies a steady state in which cell birth is balanced by cell
death. Remarkably, this steady state is maintained not only
under physiological conditions (i.e. after EP removal), but
also after additional treatment with bromocriptine or by
ovariectomy. This may suggest that under a certain threshold
level proliferation of EMR-86 tumours drops to a basal rate,
independent of residual hormonal stimuli. In this regard it is
interesting to note, that in the studies of Noble, mammary
tumours regressed and remained dormant upon substituting a
90% by a 10% oestrone-containing pellet (Noble, 1977).
With the capacity to reconstitute upon restimulation a
tumour of identical histology, DNA ploidy and growth rate
as the parent tumour, persisting EMR-86 cells could be
conceptually viewed as tumour stem-cells (Huseby, 1983;
Steel, 1977). In order to explain the phenomenon of dor-
mancy, a situation could be hypothesised analogous to the
control of erythrocyte production in the bone marrow, in
which erythroid stem cells divide continuously, irrespective of
the amount of the stimulatory hormone erythropoietin. These
cells, in addition to self-renewal, give rise to a compartment468 J.H. WIJSMAN et al.
of erythropoietin-dependent progenitor cells, that expands
rapidly in the presence of hormone, but diminishes via the
process of apoptosis in the absence of hormone (Koury &
Bondurant, 1990).
Another potentially important factor in endocrine-related
dormancy is the active role of the tumour stroma in suppor-
ting growth (Basset et al., 1990). Our observation of a
delayed decrease in LI of stromal cells compared to that of
epithelial cells indicates that the growth of stromal cells is
mediated by factors excreted by the tumour cells. It would be
of interest to know to what extent these paracrine interac-
tions are regulated by the level of circulating hormones. The
limiting factor during tumour dormancy would then be the
inability of residual epithelial cells to stimulate the stroma in
sustaining expansive growth.
In conclusion, we have developed a prolactin-dependent
tumour that becomes dormant after hormonal withdrawal.
Residual tumours do not entirely consist of non-cycling Go
cells, but remain in a steady state in which a considerable
fraction of cells continues to divide. Since the EMR-86
tumour has retained its hormone-dependency during 4 years
of transplantation and permits easy manipulation of growth
in a reproducible fashion, it provides an interesting model for
in vivo investigations of endocrine-regulated growth and dor-
mancy in tumours and their metastases.
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